|
⚲
|
| Keyboard |
| BIOS Capital Management LP
✚
|
|
|---|---|
| CRD # | 298955 |
| SEC # | 801-117544 |
| CIK # | 0001813845 |
| AUM | 250.9 M (2026-03-30) |
| Employees | 8 (75% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 817-984-9197 |
| Address | 1751 River Run Fort Worth, TX 76107 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Actuate Therapeutics Inc | 27.5 | ||
| Rexahn Pharmaceuticals Inc | 16.8 | ||
| Cognition Therapeutics Inc | 4.6 | ||
| Aileron Therapeutics Inc | 2.6 | ||
| Lantern Pharma Inc | 1.2 | ||
| In8Bio Inc | 0.2 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | BIOS I-Lumen Co-Invest I LP | [2026-03-30] | 2.5 M | 6.7 M |
| Filed 2025-06-16 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | BIOS 2024 Co-Invest LP | [2025-03-28] | 6.3 M | 16.1 M |
| Filed 2024-07-01 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | BIOS ONL Co-Invest II LP | [2025-03-28] | 7.2 M | 7.7 M |
| Filed 2024-07-01 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | BIOS Clinical Opportunity Fund LP | [2024-03-25] | 17.1 M | 17.9 M |
| Offered $50,000,000 · Filed 2023-08-04 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $32,905,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | BIOS Special Opportunity Fund II LP | 2023-03-30 | 4.0 M | |
| PE | BIOS Special Opportunity Fund LP | [2022-03-29] | 35.4 M | 16.5 M |
| Offered $35,385,080 · Filed 2022-04-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $15,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | BIOS Tech Opportunities Fund LP | 2021-09-03 | ||
| VC | BIOS Incycus Co-Invest I LP | [2018-09-19] | 2.5 M | 0.3 M |
| Offered $2,500,000 · Filed 2018-05-18 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000 · Remaining $19,720 · Duration One year or less · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 24 | 250.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 24 | 250.9 |
| By Discretionary | ||
| Discretionary | 24 | 250.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 24 | 250.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 250.9 | |
| Total | 24 | 250.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Daniel Schwarz | Executive Officer | 12 | 4 | |
| Aaron Fletcher | Director, Executive Officer | 64 | 3 | |
| Leslie Kreis Jr | Director | 42 | 3 | |
| Cavu Advisors | Director | 30 | 3 | |
| Cavu Management | Director | 30 | 3 | |
| Steelhead Capital Management | Director | 30 | 3 | |
| Bios Advisors GP | Director | 29 | 3 | |
| Bios Capital Management | Director | 29 | 3 | |
| Bios Capital Management LP | Director, Promoter | 8 | 3 | |
| Bios Advisors GP LLC | Director | 4 | 3 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001813845] | |
| 3 | [0001813845] | |
| 4 | [0001813845] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Actuate Therapeutics Inc ACTU
Warrant (Right to Buy) · derivative
|
2025-06-27 | Buy | 71,428 | $0.00 | |
|
Actuate Therapeutics Inc ACTU
Common Stock
|
2025-06-27 | Buy | 71,428 | $7.00 | 499,996 |
|
Cognition Therapeutics Inc CGTX
Common Stock
|
2025-06-18 | Grant | 34,000 | $0.00 | |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-13 | Sell | 1,903 | $3.09 | 5,880 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-13 | Sell | 7,206 | $3.09 | 22,267 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-13 | Sell | 14,218 | $3.09 | 43,934 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-13 | Sell | 4,354 | $3.09 | 13,454 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-13 | Sell | 12,319 | $3.09 | 38,066 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-12 | Sell | 2,886 | $3.38 | 9,755 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-12 | Sell | 21,557 | $3.38 | 72,863 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-12 | Sell | 18,678 | $3.38 | 63,132 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-12 | Sell | 6,601 | $3.38 | 22,311 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-12 | Sell | 10,925 | $3.38 | 36,926 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-11 | Sell | 103 | $3.40 | 350 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-11 | Sell | 171 | $3.40 | 581 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-11 | Sell | 293 | $3.40 | 996 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-11 | Sell | 45 | $3.40 | 153 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-11 | Sell | 338 | $3.40 | 1,149 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-10 | Sell | 5 | $3.40 | 17 |
|
Lantern Pharma Inc LTRN
Common Stock
|
2025-06-10 | Sell | 5 | $3.40 | 17 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Proteus LLC
✚
|
IN | 259.8 M |
|
Corinthian Capital Group LLC
✚
|
NY | 258.8 M |
|
Ma Asset Management LLC
✚
|
NY | 257.7 M |
|
Venor Capital Management LP
✚
|
NY | 254.0 M |
|
Rosenwald Capital Management Inc
✚
|
CA | 248.1 M |
|
Nexxus Holdings Advisors LLC
✚
|
CA | 246.2 M |
|
Bostwick Capital LLC
✚
|
NY | 245.4 M |
|
Kelly Park Investment LLC
✚
|
241.5 M | |
|
The Circumference Group LLC
✚
|
AR | 239.6 M |
|
Gatemore Capital Management LP
✚
|
NY | 239.5 M |